This was the number that was quoted on the Alkermes conference call today. I expect most of it came from the United States. Too bad Amylin didn't just get rid of Lilly and sign on a new global partner earlier this year and jointly with their new partner agressively launch and sell Bydureon around the world. The number $40 could easily have been double that if Amylin had the right global partner or should I say a global partner, because it appears Lilly hasn't been doing much of anything to sell Bydureon. Amylin's strategy has short changed its shareholders.